- Home
- SAMG vs AVTX Comparison
SAMG vs AVTX Comparison
Compare SAMG & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SAMG
- AVTX
- Stock Information
- Founded
- SAMG 2002
- AVTX 2011
- Country
- SAMG United States
- AVTX United States
- Employees
- SAMG N/A
- AVTX N/A
- Industry
- SAMG Investment Managers
- AVTX Biotechnology: Pharmaceutical Preparations
- Sector
- SAMG Finance
- AVTX Health Care
- Exchange
- SAMG Nasdaq
- AVTX Nasdaq
- Market Cap
- SAMG 151.1M
- AVTX 138.8M
- IPO Year
- SAMG 2013
- AVTX 2015
- Fundamental
- Price
- SAMG $16.21
- AVTX $10.66
- Analyst Decision
- SAMG
- AVTX Strong Buy
- Analyst Count
- SAMG 0
- AVTX 8
- Target Price
- SAMG N/A
- AVTX $31.00
- AVG Volume (30 Days)
- SAMG 19.9K
- AVTX 168.4K
- Earning Date
- SAMG 10-30-2025
- AVTX 11-06-2025
- Dividend Yield
- SAMG 5.18%
- AVTX N/A
- EPS Growth
- SAMG N/A
- AVTX N/A
- EPS
- SAMG 0.87
- AVTX N/A
- Revenue
- SAMG $124,451,000.00
- AVTX $441,000.00
- Revenue This Year
- SAMG $4.65
- AVTX N/A
- Revenue Next Year
- SAMG $5.26
- AVTX N/A
- P/E Ratio
- SAMG $18.64
- AVTX N/A
- Revenue Growth
- SAMG 4.13
- AVTX N/A
- 52 Week Low
- SAMG $13.54
- AVTX $3.39
- 52 Week High
- SAMG $19.20
- AVTX $16.00
- Technical
- Relative Strength Index (RSI)
- SAMG 49.33
- AVTX 60.52
- Support Level
- SAMG $15.81
- AVTX $8.65
- Resistance Level
- SAMG $16.32
- AVTX $12.41
- Average True Range (ATR)
- SAMG 0.27
- AVTX 0.89
- MACD
- SAMG -0.02
- AVTX -0.01
- Stochastic Oscillator
- SAMG 39.09
- AVTX 53.32
About SAMG Silvercrest Asset Management Group Inc.
Silvercrest Asset Management Group Inc is a wealth management firm focused on providing financial advisory and related family office services to ultra-high net-worth individuals and institutional investors. It advises clients on traditional investment strategies focused on equities, fixed income and cash as well as non-traditional investment strategies including hedge funds, private equity funds, real estate and commodities. It also provides clients with family office services and related administrative services, which include financial planning, tax planning and preparation, partnership accounting and fund administration, and consolidated wealth reporting. The company derives revenues principally from assets under management.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).